

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

Results of the ATTRibute-CM Trial

Julian D. Gillmore,¹ Daniel P. Judge,² Francesco Cappelli,³ Marianna Fontana,¹ Pablo Garcia-Pavia,^{4,5,6} Simon Gibbs,⁷ Martha Grogan,⁸ Mazen Hanna,⁹ James Hoffman,¹⁰ Ahmad Masri,¹¹ Mathew S. Maurer,¹² Jose Nativi-Nicolau,¹³ Laura Obici,¹⁴ Frank Rockhold,^{15, 16} Keyur B. Shah,¹⁷ Prem Soman,¹⁸ Jyotsna Garg,¹⁵ Karen Chiswell,¹⁵ Haolin Xu,¹⁵ Xiaofan Cao,¹⁹ Ted Lystig,¹⁹ Uma Sinha,¹⁹ and Jonathan C. Fox¹⁹

¹National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK; ²The Medical University of South Carolina, Charleston, SC, USA; ³Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy; ⁴Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta der Hierro Majadahonda, CIBERCV, Manuel de Falla 2, 28222 Madrid, Spain; ⁵Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcon, Spain; ⁶European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart; ⁷The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Eastern Health Clinical School, Box Hill, Victoria, Australia; ⁸Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA; ⁹ Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA; ¹⁰ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; ¹¹Cardiac Amyloidosis Program, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA; ¹²Cardiac Amyloidosis Program, Division of Cardiology, Columbia College of Physicians and Surgeons, New York NY, USA; ¹³ Amyloidosis Program, Department of Transplant, Mayo Clinic, Jacksonville, FL, USA; ¹⁴Amyloidosis Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; ¹⁵Duke Clinical Research Institute, Durham, NC, USA; ¹⁶Duke University Medical Center, Durham, NC, USA; ¹⁷The Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA; ¹⁸Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ¹⁹BridgeBio Pharma, San Francisco, CA, USA

27 Aug 2023



Disclosures

**Advisor/consultant for BridgeBio, Alnylam, Ionis,
AstraZeneca, Intellia, Pfizer, ATTRalus, Lycia**

Acoramidis is an investigational molecule. The safety and efficacy have not been fully evaluated by regulatory authorities.

ATTRibute-CM: Study Design

Key eligibility criteria

- Subjects with diagnosed ATTR-CM (WT or variant)
- NYHA Class I-III
- ATTR-positive biopsy or 99mTc scan
- Light chain amyloidosis excluded if diagnosis by 99mTc

Screening and randomization

800 mg acoramidis HCl twice daily

N = 421

placebo twice daily

N = 211

Efficacy assessment included 611 participants in the pre-specified mITT population (eGFR \geq 30 mL/min/1.73 m²)

Tafamidis usage allowed after Month 12

30-month primary endpoint:

Hierarchical analysis consisting of all-cause mortality, cumulative frequency of CVH, change from baseline in NT-proBNP, and change from baseline in 6MWD

800 mg acoramidis HCl twice daily

Open-label extension

6MWD = Six-minute walk distance; NYHA = New York heart association; 99mTc = Technetium labeled pyrophosphate (PYP) or bisphosphonate (e.g., DPD); mITT = Modified intent-to-treat. eGFR = Estimated glomerular filtration rate. ClinicalTrials.gov identifier: NCT03860935.


ATTRibute-CM: Baseline Demographic Characteristics

Characteristic	Acoramidis (N=421)	Placebo (N=211)
Age (years), mean (SD)	77.4 (6.5)	77.1 (6.8)
Male sex, n (%)	384 (91.2)	186 (88.2)
ATTRwt-CM, n(%)	380 (90.3)	191 (90.5)
NT-proBNP (pg/mL), median (IQR)	2326 (1332, 4019)	2306 (1128, 3754)
eGFR (mL/min/1.73m ²), mean (SD)	60.9 (18.2)	61.0 (18.7)
TTR (mg/dL), mean (SD)	23.2 (5.6)	23.6 (6.1)
KCCQ-OS, mean (SD)	71.5 (19.4)	70.3 (20.5)
6MWD (m), mean (SD)	361.2 (103.7)	348.4 (93.6)
Concomitant tafamidis use, n (%) [*]	61 (14.5)	46 (21.8)

ATTRwt-CM = Transthyretin amyloidosis wild-type cardiomyopathy; NT-proBNP = N-terminal pro-B-type natriuretic peptide; IQR = interquartile range; TTR = transthyretin; KCCQ-OS = Kansas City cardiomyopathy questionnaire overall summary score.


^{*}Tafamidis usage allowed after Month 12.

ATTRibute-CM: Primary Outcome Overall and by Subgroups



FS = Finkelstein-Schoenfeld; CI = Confidence interval.


ATTRibute-CM: All-Cause Mortality



ARR = Absolute risk reduction; RRR = Relative risk reduction.

All-cause mortality includes heart transplant, implantation of cardiac mechanical assist device, and all-cause death.

ATTRibute-CM: Cardiovascular-Related Mortality




CV-related: Cardiovascular-related.

¹Heart transplant and implantation of cardiac mechanical assistance device (CMAD) were treated as death for this analysis. N = 1 heart transplant & N = 1 CMAD implantation in placebo group.

²CV-related mortality includes all adjudicated CV-related and undetermined cause of death.


ATTRibute-CM: Frequency of CVH; P<0.0001 on overall analysis




Negative binomial regression with treatment group, stratification factors, and subgroup of interest was used to analyze the cumulative frequency of adjudicated CV-related hospitalization.

ATTRibute-CM: Change from Baseline in NT-proBNP & 6MWD

Change from Baseline in NT-proBNP¹




Change from Baseline in 6MWD¹



¹Analyzed using mixed effects model with repeated measures. Missing measurements due to early discontinuation imputed using the Jump to Reference method. Missing measurements due to death performed by sampling with replacement from bottom 5% of observed values.


ATTRibute-CM: Change from Baseline in KCCQ-OS & Serum TTR

Change from Baseline in KCCQ-OS¹



Acoramidis	408	263	389	390	397	404	407	405
Placebo	202	134	192	194	196	199	201	201

Change from Baseline in Serum TTR²




Acoramidis	406	363	348	324	319	328	307	300	294	297	280	283
Placebo	199	178	175	165	162	168	160	160	154	142	128	135


¹Analyzed using mixed effects model with repeated measures. Missing measurements due to early discontinuation imputed using the Jump to Reference method. Missing measurements due to death performed by sampling with replacement from bottom 5% of observed values. ²Observed measurements without any imputation. No adjustment was made for early discontinuation for any reason, including death.

ATTRibute-CM: Improvements in Disease Measures

Improvement from baseline in NT-proBNP



Improvement from baseline in 6MWD



miTT population. Improvement is defined as <0 pg/mL change from baseline to month 30 for NT-proBNP; >0 meter change from baseline to month 30 for 6MWD. In both cases, among subjects with both baseline and month 30 values.

ATTRIBUTE-CM: Patient Safety

Subjects with one or more event(s)	Acoramidis N=421 N (%)	Placebo N=211 N (%)
Any treatment-emergent adverse events (TEAEs)	413 (98.1%)	206 (97.6%)
TEAE with fatal outcome	60 (14.3%)	36 (17.1%)
TEAE leading to hospitalization	212 (50.4%)	128 (60.7%)
TEAE leading to study drug discontinuation	39 (9.3%)	18 (8.5%)
Any treatment-emergent serious adverse events (SAEs)	230 (54.6%)	137 (64.9%)
Treatment-emergent SAEs leading to study drug discontinuation	21 (5.0%)	15 (7.1%)
Severe TEAEs ¹	157 (37.3%)	96 (45.5%)

Acoramidis was generally well-tolerated with no findings of potential clinical concern

All Adverse Events (AEs) occurring during the treatment period are considered treatment-emergent adverse events (TEAEs). Serious Adverse Event (SAE) meets seriousness criteria.

¹Severity as assessed by the investigator.

ATTRibute-CM: Conclusions

- **Primary endpoint analysis (Finkelstein-Schoenfeld hierarchy of ACM, CVH, NT-proBNP, 6MWD) highly statistically significant**
 - Win ratio 1.8; $p < 0.0001$; 58% of win ratio ties broken by ACM + CVH
- **Consistent treatment effect across secondary endpoints**
 - Better preservation of functional capacity (6MWD) and QoL (KCCQ-OS)
 - Reduced progressive increase in NT-proBNP; 45% of patients improved
- **81% survival rate on acoramidis approaches survival rate in age-matched US database (~85%)^{1,2}**
- **0.29 mean annual CVH frequency on acoramidis approaches annual hospitalization rate observed in broader US Medicare population (~0.26)³**
- **Reassuring safety profile**

¹ssa.gov. ²Miller et al., Am J Card 2021 ³US Department of Health & Human Services, Jan 2018.

ATTRIBUTE-CM: Acknowledgements

- **Patients, caregivers**
- **Investigators, research staff**
- **Steering Committee, Data Monitoring Committee, Clinical Events Committee, Data Reporting Center**
- **Patient advocacy organizations**
- **BridgeBio scientists and supporting employees**